Open AccessFlorical and Early Otosclerosis
Author(s) -
Cheng Jeffrey,
Chandrasekhar Sujana S.,
Del Signore Anthony
Publication year - 2011
Publication title -
otolaryngology–head and neck surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.232
H-Index - 121
eISSN - 1097-6817
pISSN - 0194-5998
DOI - 10.1177/0194599811415823a258
Subject(s) - medicine , otosclerosis , hearing loss , adverse effect , surgery , audiology
Objective Report our results with Florical in stabilizing hearing loss in patients with early otosclerosis. Method A retrospective chart review was undertaken of patients with early otosclerosis treated with Florical. Using a paired t test, comparisons were made in amount of change between speech recognition threshold (SRT) and pure tone average (PTA) air‐bone gap (ABG). A P ‐value of <. 05 was considered statistically significant. Results Eight patients with 10 affected ears were studied. Average age was 44.1 ± 14.2 years old. No statistically significant decline was detected at 3, 6, and 12 months in SRT ( P ‐value = 1.0,. 68,. 68, respectively) and PTA ABG ( P ‐value =. 46,. 61, and. 39, respectively). Baseline average ABG was 10.5 ± 8.7 dB. Eight of the 10 ears experienced improvement of PTA ABG (mean = 6.6 ± 5.7 dB). One patient (1 ear) had complete closure of the PTA ABG. Mean follow‐up was 5.7 months. No patients discontinued use of Florical because of adverse side effects. Only 2 patients (25%) reported dyspepsia. Conclusion Our early experience demonstrates that Florical may prevent hearing deterioration and even reversal of early conductive hearing loss. It may be better tolerated than other sodium fluoride preparations, as calcium carbonate may help to alleviate the gastrointestinal side effects associated with sodium fluoride administration.